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A B S T R A C T
The exact incidence and mortality rate in Bosnia and Herzegovina are unknown as there are no National Cancer Reg-
ister. The available data are mostly based on the estimation from neighboring countries. Therefore, the aim of this study
was to present the preliminary but more accurate estimates of cervical cancer incidence and mortality rates in Bosnia
and Herzegovina. The data on cervical cancer cases in Bosnia and Herzegovina were collected from different sources and
varies depending on the size of the city or region. To calculate the crude rates for the period from 2000 to 2008, we used
the Bosnian and Herzegovinian population census for 1991. Thus, the crude incidence rate in Sarajevo region is more
equable (app. 30.4/100,000 women-year), while in Tuzla Canton it varied from 18.5 in 2005 to 4.8/100,000 in 2000. In
Tuzla Canton, in the period 1993–2006, 27.1% of all women with cervical cancer were younger than 30. However, the ex-
act crude incidence in Bosnia and Herzegovina could be even higher. Data from Tuzla Canton showed slight increase in
mortality rate in the last 5 years (4.9/100,000), with the peak in 2007 (7.0/100,000). The presented data reflects the situa-
tion throughout Bosnia and Herzegovina and underline the necessity of the implementation of cervical cancer register
and organized screening program.
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Introduction
Cervical cancer is the second most common cancer in
women worldwide, with the majority of cases (~80%) oc-
curring in developing countries1 where cervical cancer
accounts for 15% of female cancers, with a risk before age
65 of 1.5%2. Cervical cancer is preventable, but most
women in developing countries do not have access to ef-
fective screening programs. Despite the sufficient evi-
dence for the effectiveness of screening by cytology in
preventing cervical cancer, screening policies vary widely
among European countries3 and incidence is increasing
in younger women4.
Cervical cancer prevention in South-East Europe is
hardly documented, in spite of the fact that it encloses
the most affected countries of Europe5. Opportunistic
screening was introduced in regular gynaecological prac-
tice in Bosnia and Herzegovina at the same time as in
other republics of the former Yugoslavia. However, there
are no population based cancer register nor cervical can-
cer or Pap test database in the country. In addition, there
is no plan to establish a proper cervical cancer preven-
tion program in Bosnia and Herzegovina.
According to the Globocan 20026 the estimated inci-
dence for cervical cancer in Bosnia and Herzegovina was
18.7/100.000 women-year. In the study from 2007 of
Arbyn and co-workers7, which evaluated the burden of
cervical cancer in 11 countries in the South-Eastern part
of Europe (Albania, Bosnia and Herzegovina, Bulgaria,
Croatia, Cyprus, Greece, FYROM (Former Yugoslavian
933
Received for publication May 28, 2013
Republic of Macedonia), Moldova, Romania, Serbia and
Montenegro, and Slovenia) the cervical cancer incidence
in Bosnia and Herzegovina was estimated to be 21.3/
100.000 (crude incidence was 26.6/100.000).
Available data from Medline and PubMed about the
cervical cancer incidence and mortality in Bosnia and
Herzegovina are estimated data based on the incidence
and mortality determined in the neighboring countries.
The most recent mortality rates of cervical cancer in the
study of Arbyn and co-workers7 were derived from the
published vital statistics, stored at the World Health Or-
ganisation (WHO) Mortality Database for all countries
except Cyprus and Bosnia and Herzegovina. The mortal-
ity rate for Bosnia and Herzegovina was estimated by av-
eraging rates from neighboring countries to be 8.0/
100.000 (crude rate was 11.1/100. 000)7.
Thus, the aim of this study is to present the first pre-
liminary but accurate estimates on cervical cancer inci-
dence and mortality rates in Bosnia and Herzegovina




Information about cervical cancer cases in Bosnia and
Herzegovina was collected from different sources at hos-
pital’s or University clinical center’s registries and Insti-
tute for Public Health. All cervical cancer cases were bi-
opsy confirmed. The most detailed data was gathered in
Tuzla Canton, from University Clinical Centre Tuzla
and Institute of Public Health of Tuzla Canton. Only
data for cervical cancer (ICD-10 code C53), without data
on death associated to »Uterus not otherwise specified«
(NOS) (ICD-10 code C55) are presented.
Cases of death from cervical cancer are likely to be
overestimates since there are almost one hundred deaths
per year from cancer of uterus NOS in Bosnia and
Herzegovina and a proportion of these are probably due
to cervical cancer as well. To calculate the crude rates for
the period 2000–2008, we used the Bosnian and Herze-
govinian population census for 1991. The lack of new
census in Bosnia and Herzegovina and a number of mi-
grations in post war period made it impossible to calcu-
late the world age-standardized incidence rate.
Statistical analysis
Methods of descriptive statistics were used. Crude in-
cidence, as well as mortality rates, were calculated per
100.00 female citizens. Differences between the frequen-
cies among groups were calculated using c2 test.
Statistical analyses were performed using GraphPad
Prism 5 software (San Diego, California, USA) and prob-
ability values of p<0.01 were accepted as significant ac-
cording to Bonferroni correction for 5 tests. Statistically
significant differences are presented as: p<0.05; p<0.01
and p<0.001.
Results
As data were collected from various sources, the time
period is not uniform (Figure 1).
Figure 1 Number of new cervical cancer cases in dif-
ferent regions and towns in Bosnia and Herzegovina in
the period from 2000 to 2006; *data from local hospitals
gathered in Travnik, Nova Bila, small towns in the Cen-
tral Bosnia, and Mostar East and West, respectively;
**data from bigger regions, the University Clinical Cen-
ters of Sarajevo Canton and the Tuzla Canton, and data
from the Clinical Centre and the Regional Hospital of
Banja Luka and USK, respectively.
Sarajevo and Tuzla are University Clinical Centers
and the biggest regions in Federal part of Bosnia and
Herzegovina with 465 000 and 498 549 inhabitants, re-
spectively. Banja Luka is the biggest city in the Repu-
blika Srpska of Bosnia and Herzegovina with 195 692 in-
habitants and it has a regional Clinical Center. The East
and the West Mostar (75 865 inhabitants), Travnik (70
047 inhabitants) and Nova Bila (770 inhabitants) have
Hospitals or Regional Medical Center, while USK (Una-
-Sana Canton) with a Regional Hospital, which is cover-
ing several more towns, Biha}, Cazin, Sanski Most and V.
Kladu{a (together 288 114 inhabitants). The crude inci-
dence rate for cervical cancer is different in the two big-
gest regions in Bosnia and Herzegovina, Sarajevo and
Tuzla (Figure 2).
The most detailed data were for Tuzla Canton, which
is the most populated canton in Bosnia and Herzegovina,
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Fig. 1. Number of new cervical cancer cases in different regions
and towns in Bosnia and Herzegovina in the period from 2000 to
2006; *data from local hospitals gathered in Travnik, Nova Bila,
small towns in the Central Bosnia, and Mostar East and West,
respectively; **data from bigger regions, the University Clinical
Centers of Sarajevo Canton and the Tuzla Canton, and data
from the Clinical Centre and the Regional Hospital of Banja Lu-
ka and USK, respectively.
with more than 200,000 women, above the age of 14.
Tuzla Canton includes 19 cities with their neighboring
villages. The age distribution of cervical cancer in Tuzla
Canton was gathered from the registry of malignant dis-
eases of Institute for Public Health of Tuzla Canton (Ta-
ble 1).
The incidence and mortality rate in Tuzla Canton
varied significantly in the period from 2000 to 2008 (Fig-
ure 3). Cervical cancer is the most common form of gy-
naecological malignancy in Tuzla Canton with 48.9% of
all female cancers.
The crude incidence from 2008 year was significantly
lower than the incidence 2000 year (p<0.001). On the
other side, cervical cancer mortalities did not differ be-
tween 2000 and 2008 year (p>0.05). Only 20.4% women
being in an operable stage at the time of diagnosis, while,
the rest received the appropriate therapeutic modalities
(irradiation, chemotherapy or the combination of both).
According to the preliminary data gathered from the
population registry until present shows that most of the
women diagnosed with the cervical cancer are at the age
between 41 to 50, while 1.5% are younger than 20.
Discussion
Cervical cancer still constitutes a considerable public
health problem in Europe. The dramatic contrast be-
tween West and East European states merits particular
attention from the health authorities of the countries
concerned and the EU as a whole. The differences within
Europe is largely due to the absence of effective cervical
screening in Eastern Europe and the implementation of
properly organized cervical screening programs which
would inevitably have a major impact on this disease. Ini-
tiation and sustenance of cervical cytology programs in-
volving the screening of sexually active women annually,
or once in every 2–5 years, have resulted in a large de-
cline in cervical cancer incidence and mortality8. The sit-
uation of cervical cancer prevention in most of the coun-
tries of former Yugoslavia is hardly well established, in
spite of the fact that opportunistic screening is on since
the 1960s.
Serbia and Montenegro had the world-age standard-
ized incidence rate of 27.3/100.000, while Croatia 13.3/
100,000 in 20046. Slovenia records the incidence increase
since 1994 with the peak in 1996 of 23/100.0009. Accord-
ing to the latest report of Globocan 2008, those countries
of former Yugoslavia show decline of incidence. Age-stan-
dardized incidence rates for Serbia is 20.9; Montenegro
13.0 (separate countries from 2006); Croatia 11.8 and
Slovenia 11.110. On the other hand, the developed coun-
tries have seen their cervical cancer incidence and mor-
tality rates decline. Cervical cancer incidence has been
E. Iljazovi} et al.: Cervical Cancer and Mortality Rate, Coll. Antropol. 38 (2014) 3: 933–937
935
TABLE 1
THE AGE DISTRIBUTION OF CERVICAL CANCER CASES AT THE TUZLA CANTON GATHERED FROM THE REGISTRY
OF MALIGNANT DISEASES AT THE INSTITUTE OF PUBLIC HEALTH OF THE TUZLA CANTON
Age/year 2000 2001 2002 2003 2004 2005 2006 2007 2008 Total
0–20 1 1 2 1 2 2 9
20–30 3 2 3 4 1 4 2 0 5 24
31–40 25 17 12 10 5 6 5 8 4 92
41–50 30 30 16 29 18 12 19 17 25 196
51–60 22 22 15 17 16 10 13 18 12 145
61–70 26 15 7 9 10 11 10 11 17 116
71–80 6 7 5 6 7 3 3 4 4 45
over 80 1 0 0 1 1 2 1 1 4 11

































































Fig. 2. The crude rate of cervical cancer per 100,000 women-years





























Fig. 3. The crude rate of cervical cancer per 100,000 women-years
and mortality rate at Tuzla Canton in the period from 2000 to
2008.
less than 10/100,000 women in countries with effective
organized screening program, such as Finland and Uni-
ted Kingdom11.
Bosnia and Herzegovina does not have a population
based registry of malignant disease, nor the Pap test da-
tabase and mostly dispose with data of individual study
or cantonal registries. Last population census was at
1991 which affect the statistical analysis. Number of new
cases of cervical cancer per year in Bosnia and Herzego-
vina varies depending on the size of the city or region.
The most relevant data close to the real incidence in the
country was gathered in Sarajevo Canton and Tuzla Can-
ton, both being the biggest regions in Bosnia and Her-
zegovina. The crude incidence rate in the Sarajevo Can-
ton is more homogenous, while in the Tuzla Canton
varied from 18.5/100.000 in 2005 to 43.8/100.000 in 2000.
This wide range could be explained with the fact that
Tuzla Canton is the most populated region in Bosnia and
Herzegovina and also the region to which gravitates cer-
tain number of small towns from east part of country
(out of region of Tuzla Canton). According to the recent
study in East Europe, based mostly on the estimation
from neighboring countries, crude incidence rate for
Bosnia and Herzegovina is 26.68. Considering data from
this study, the exact crude incidence in the country could
be even higher. The highest incidence from the countries
of the former Yugoslavia has Serbia with incidence of
32.5–38.1/100.000 women in Belgrade region, but lower
in Ma~vanski region, 16.6/100.00012. Croatia, which is
the first Bosnian neighbor in the west, north and south
has lower cervical cancer incidence than Bosnia (13.3/
100.000 women-years)13. Increased incidence and even
mortality in young women was first noticed in England
and Wales but was subsequently observed in other Euro-
pean countries14. The most complete epidemiological da-
ta were available for Tuzla Canton. One of the previous
studies in this region, as well as this study, showed that
the most of the women with cervical cancer were in fifth
decade of life with 1.5% of women younger than 20. In
the study of Fatu{i} and co-workers15,16 (2007) 27.11% of
all women with cervical cancer are younger than 30 in
period 1993–2006. This high percentage of younger age
in incidence rate could be explained with war and post –
war period (1993–2000) and diminished motivation in
general of women for this type of health control. High in-
cidence in Tuzla Canton, with significant proportion of
young women and high percentage of women with ad-
vance disease are the consequence of lack of the screen-
ing program. Bosnia and Herzegovina has only an oppor-
tunistic screening program. Opportunistic or unorganized
screening also decrease cervical cancer rates, although
not to the extent of organized programs, also this kind of
program may not adequately cover the population tar-
geted, sometimes missing those at highest risk17,16.
Ferlay and co-workers analyzed the cancer incidence
and mortality rate in Europe in 2006, for 38 European
countries. The most data in this study were obtained
from the national cancer registries, annual reports on
the website, and civil registration systems recording vital
events (births, marriages, deaths). No data were avail-
able for Cyprus and Bosnia Herzegovina. The country-
-specific incidence and mortality rates for these two
countries were calculated from the simple average of
those of neighboring countries (Greece and Malta; Alba-
nia, Macedonia and Serbia and Montenegro, respectively)6.
High world-age standardized mortality rates (>7.5/100.000
women-years) are observed in 7 countries: FYROM (7.6),
Moldova (7.8), Bulgaria (8.0), Bosnia and Herzegovina
(8.0), Albania (9.8), Serbia and Montenegro (10.1) and
Romania (13.0)8.
Data from Tuzla Canton showed slight increase in
mortality rate in last 5 years, (4.9/100,000 women-years),
with the peak in 2007 (7.0/100.000), and then, slight de-
crease in 2008 (4.7/100.000). Mortality rate in neighbor-
ing countries are similar to results we found in Tuzla
Canton; Croatia (5.0/100.000) Serbia (7.0/100.000) and
Slovenia (5.0/100.000)18,12. The explanation for this slight
increasing in mortality rate in Tuzla Canton might be
the advance disease at the time of diagnosis, but also
better reporting of cause of death and more precise cod-
ing of cervical cancer instead of uterine cancer NOS.
Summary report of WHO/IQO and IARC Globocan
200819,20 reported that the crude incidence rate in Bosnia
and Herzegovina is 13.2, almost half of the crude inci-
dence noticed in the work of Arbyn and co-workers. The
both results were derived from estimates of incidence in
the countries of former Yugoslavia and Southern Europe,
which, according to the same source, noticed the decline
of the cervical cancer incidence (particularly Serbia and
Croatia) (IARC, Globocan, 2008; WHO/IQO, 2010). In
the Summary report from WHO/IQO there are not avail-
able data from the Bosnia and Herzegovina.
The lowest incidence rate in Europe is in Finland
with 4 cases per 100,000 women-years, and with orga-
nized cervical cancer screening since early 1960’s21. The
lowest mortality rates, particularly in younger women
(age 20–44) in Finland (0.5/100.000) or Sweden (0.9/
100.000), were largely due to organized screening22. Mor-
tality rates currently observed in Eastern Europe are
similar to those observed in Western Europe several de-
cades ago.23
Conclusion
The fluctuation of the incidence according to the liter-
ature data and this study reflects the situation through-
out Bosnia and Herzegovina regarding cervical cancer in-
cidence and mortality. It also indicates the urgent need in
the near future to establish a national registry of malig-
nant diseases, the Pap test database within an organized
cervical cancer prevention programs as recommended by
the European Council Recommendation22.
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PROCJENA INCIDENCIJE RAKA CERVIKSA I STOPE MORTALITETA U BOSNI I HERCEGOVINI
S A @ E T A K
To~na incidencija i stopa mortaliteta u Bosni i Hercegovini se ne zna jer ne postoji nacionalni registar raka. Dostu-
pni podaci temelje na procjeni iz susjednih zemalja. Stoga je cilj ovog istra`ivanja bio prezentirati preliminarne, ali
preciznije procjene incidencije raka vrata maternice i stope smrtnosti u Bosni i Hercegovini. Podaci o slu~ajevima raka
vrata maternice u Bosni i Hercegovini su prikupljeni iz razli~itih izvora, a variraju ovisno o veli~ini grada ili regiji. Za
izra~un grube stope za razdoblje od 2000. do 2008. godine, koristili smo bosanskohercegova~ki popis stanovni{tva iz
1991. godine. Dakle, gruba stopa incidencije u regiji Sarajevo je vi{e ujedna~ena (oko 30,4/100,000 `ena-godina), dok u
Tuzlanskom kantonu varira od 18,5 u 2005. godini do 4,8/100,000 u 2000. Godini. Na podru~ju Tuzlanskog kantona, u
razdoblju od 1993. do 2006. 27,1% svih `ena s rakom grli}a maternice su bile mla|e od 30 godina. Me|utim, to~na gruba
incidencija u Bosni i Hercegovini mogla bi biti ~ak i ve}a. Podaci iz Tuzlanskog kantona pokazali su blagi porast stope
smrtnosti u posljednjih 5 godina (4,9/100,000), a najvi{e u 2007. godini (7,0/100,000). Prezentirani podaci odra`avaju
situaciju na cijelom teritoriju Bosne i Hercegovine te nagla{avaju potrebu provedbe registra za rak cerviksa i organizi-
ranog programa pregleda.
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